Circio Holding ASA

Circio invites to R&D and corporate update webcast on 28 May 2025

· CTO Dr. Thomas B Hansen will present a summary of recent in vivo results

validating circVec performance in novel AAV and DNA formats for gene and cell

therapy

· CEO Dr. Erik D Wiklund will provide a corporate and business development

update, incl. information related to the upcoming annual general meeting

Oslo, Norway 22 May 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology

company developing powerful circular RNA technology for next generation nucleic

acid medicine, invites to a live webcast at 10:00am CEST on Wednesday 28 May

In the webcast, CTO Dr. Thomas B Hansen will present Circio´s latest circVec

platform in vivo results. Recent findings include validation of the circVec

platform using novel AAV and DNA vector formats, and demonstrate enhanced and

distinct tissue expression profiles vs. equivalent conventional mRNA-based

vectors. The results highlight potential applications for circVec in tissue

targeted gene therapy and in vivo cell therapy; a field that is advancing

rapidly and gaining strong momentum in the industry.

CEO Dr. Erik D Wiklund will provide a corporate update including business

development activities and background and practical information relating to

proposals for shareholder approval at the annual general meeting to be held on 5

June 2025.

Presenters:

CEO Dr. Erik Digman Wiklund

CTO Dr. Thomas Birkballe Hansen

Time: 10:00 CEST on 28 May 2025

Click here to access Teams

webcast (https://teams.microsoft.com/meet/3919530790393?p=D2tS9HOrDxAFf5WhLj)

Meeting ID: 391 953 079 039 3

Passcode: PB2gk7wt

Questions can be submitted in advance by email to Erik D Wiklund:

[email protected] or directly in the live webcast

A recording of the webcast will be made available on the Circio

webpage (http://www.circio.com/)

AI Terminal